Effect of direct-acting antiviral drugs on portal circulation hemodynamics in cirrhotic patients infected with HCV

Autor: Alshymaa A. Hassnine, Wail Soliman, Amr M. Elsayed, Mahmoud M. Higazi, Mery Saied, Ehab M. Abdelraheem

Publikováno v: Egyptian Liver Journal, Vol 12, Iss 1, Pp 1-6 (2022)

Abstract Background Liver cirrhosis (LC) is the most common cause of portal hypertension. In chronic hepatitis C patients who are treated with direct-acting antiviral therapy (DAAS), the progression of cirrhosis can be reversed with treatment. Portal

Externí odkaz: https://doaj.org/article/4b8ba0d3aa9743c1aa6f1aa7bd123d1f

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Hepatitis C virus- related cryoglobulinemic vasculitis: A review of the role of the new direct antiviral agents (DAAs) therapy

Autor: Valter Gattei, Maurizio Tonizzo, Gabriele Pozzato, Marcella Visentini, Endri Mauro, Cesare Mazzaro, Pietro Andreone, Luigino Dal Maso

Hepatitis C virus (HCV) infection affects about 70 million people worldwide. HCV is responsible for both hepatitis and extra-hepatic manifestations. Chronic infection has been shown to develop in about 70% of cases and can progress to cirrhosis or he

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92bed928bbbaf17b67ccbe4e9e4cef38
http://hdl.handle.net/11368/2968238

Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents

Autor: A. Licata, Luigi Guarneri, G. Rigano, Carlo Saitta, G. Raimondo, E. Frazzetto, Giuseppe Montalto, S. Maimone, Federica Latteri, I. Scalici, G. Fuduli, A. Craxì, Giuseppe Cabibbo, Anna Licata, C. Cammà, A. Ficalora, F. Di Lorenzo, Marco Distefano, Francesca Savalli, A. Bellia, Giovanni Mazzola, Antonio Magro, Fabio Tinè, M. Distefano, Lydia Giannitrapani, M.R. Alinovi, E. Falzone, F. Tinè, F. Benanti, L.N. Larocca, F. Cartabellotta, G. Cabbibbo, V. Calvaruso, A. Digiacomo, Salvatore Petta, M.A. Di Rosolini, Giuseppe Malizia, Bruno Cacopardo, F. Lomonaco, Vincenza Calvaruso, Marcello Maida, Adriana Sanfilippo, Giuseppa Caccamo, S. Madonia, Giovanni Squadrito, G. Squadrito, Marco Barbara, M. Russello, Gaetano Bertino, L. Larocca, A. Salvo, F. Maffeo, I. Scalisi, G. Scifo, Vito Di Marco, V. Di Marco, L. Giannitrapani, Luigi Mondello, Maria Antonietta Di Rosolini, V. Portelli, A. Smedile, G. Mazzola, Giovanni Raimondo, Antonio Cascio, S. D’Andrea, Carmelo Iacobello, Maurizio Russello, F. Pulvirenti, Antonio Craxì, Calogero Cammà, Salvatore Madonia, A.L. Ardiri, R. Vassallo, R. Benigno, F. Savalli, Alessandro Bellia, T. Prestileo, A. Averna, L. Guarneri, A. Magro, A. Davì, Tullio Prestileo, C. Iacobello, P. Colletti, G. Bertino, Arturo Montineri, Antonio Davì, I. Cacciola, Irene Cacciola, G. Gioia, Giuseppe Alaimo

Background & Aims: Studies have produced conflicting results of the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C virus–associated cirrhosis treated with direct-acting antivirals (DAAs). Data from clinics are needed to ac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd4e9e6cb9d628dbfdede0657dbd0bb9
http://hdl.handle.net/11570/3128437

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.